Boryung announced on the 28th that it has officially launched Zepzelca, a new small-cell lung cancer drug, in Korea. Zepzelca is a new anticancer drug developed by PharmaMar S.A. It is used for metastatic small-cell lung cancer that has failed first-line platinum-based chemotherapy. Zepzelca is a new drug with a mechanism that simultaneously shows 'apoptosis of cancer cells through inhibition of DNA transcription' and inhibition of cancer cell proliferation, immune checkpoint action, and angiogenesis through suppression of transcriptional activity in Tumor-Associated Macrophage (TAM). Zepzelca was approved by the Ministry of Food and Drug Safety in September of last year and will be distributed to medical institutions